According to a recent LinkedIn post from Click Therapeutics Inc, founder and CEO David Benshoof Klein is scheduled to speak at the US Pharma and Biotech Summit hosted by FT Live with Endpoints News on May 14. The post highlights his planned focus on Over-the-Counter Digital Therapeutics, or ODTx, which are described as bridging consumer wellness tools and medical-grade software.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that Click Therapeutics sees an opportunity to convert passive biometric data from wearables and apps into actionable treatment interventions. For investors, this positioning could signal a strategic push toward scalable, consumer-facing digital health offerings that may complement traditional prescription-based digital therapeutics.
As shared in the post, the session will examine how consumer health technology may reshape healthcare delivery, access, and system value. Increased visibility at a high-profile industry summit could enhance Click Therapeutics’ profile among pharma partners and payers, potentially supporting future collaboration, distribution, and monetization opportunities if the ODTx category gains traction.